ArabFinance: Sabaa International for Pharmaceutical and Chemical Industry (SIPC) has expected to produce two medicines to treat coronavirus ahead of the 2020 end, Director of Sabaa’s Development Department Rami al-Hendawi told Al-Mal news website.

The company has intended to launch 3 immunomodulatory drugs, al-Hendawi said.

The medicines production will be started before 2020’s end subject to regulatory approvals with the self-financed budget of EGP 15 million.

The production capacity of the medicines will be determined by the orders the company will receive from the hospitals and will be delivered through 3 weeks.

The company obtained earlier preliminary approval from the Egyptian Drug Authority to register Favipiravir (200 mg) tablet, one of the drugs used in the treatment of coronavirus.

Sabaa is an Egypt-based company engaged in the pharmaceutical sector. The company’s generic product portfolio includes products focused on different therapeutic categories.

 

Copyright © 2020 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.